SM
Therapeutic Areas
Evexta Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rupitasertib (DIACC3010) | ER+ HER2- Advanced Breast Cancer (combination with SERD) | Phase 1b (planned for 2026) |
| EVX020 | Hematologic Malignancies (as ADC payload) | Discovery |
| Drug | Indication | Phase |
|---|---|---|
| Rupitasertib (DIACC3010) | ER+ HER2- Advanced Breast Cancer (combination with SERD) | Phase 1b (planned for 2026) |
| EVX020 | Hematologic Malignancies (as ADC payload) | Discovery |